{
  "round": 2,
  "request": {
    "reason": "机制连通性不足，冲突热点集中在副作用与疗效证明上，需引入新种子以扩大覆盖。",
    "n": 4
  },
  "prev_hypotheses": [
    "Infliximab",
    "Adalimumab",
    "Apremilast",
    "Acitretin",
    "Methotrexate",
    "Cyclosporine",
    "Etanercept",
    "Vedolizumab",
    "Ustekinumab",
    "Secukinumab",
    "Brodalumab",
    "Tazarotene"
  ],
  "status": "regenerated",
  "generated_seeds": [
    "Acitretin",
    "Adalimumab",
    "Apremilast",
    "Brodalumab",
    "Etanercept",
    "Guselkumab",
    "Infliximab",
    "Ixekizumab",
    "Methotrexate",
    "Secukinumab",
    "Tildrakizumab",
    "Ustekinumab"
  ],
  "new_hypotheses": [
    "Acitretin",
    "Adalimumab",
    "Apremilast",
    "Brodalumab",
    "Etanercept",
    "Guselkumab",
    "Infliximab",
    "Ixekizumab",
    "Methotrexate",
    "Secukinumab",
    "Tildrakizumab",
    "Ustekinumab"
  ]
}